Andres Maldonado

Kelly Shi

Louise Chen

Joe Catanzaro

Albert Lowe

Bing Zhao

Gil Blum

Joseph Catanzaro

Qu Xiaoyi

Yingqi Peng

Zhuxuan Jiang

- NovaBridge Biosciences' subsidiary, Visara, **assigned its exclusive license for VIS-101** to Everest Medicines for development, manufacture, and commercialization in Greater China, Singapore, South Korea, and certain other Asian countries on **October 28, 2025**.  **[1778016_0001193125-25-256922_everest_and_woo_pr_10-29.htm:0]** **[1778016_0001193125-25-256922_imab-ex99_1.htm:0]**  Everest Medicines will assume all payment obligations under the assigned license agreement and reimburse Visara for any upfront payments already made.  **[1778016_0001193125-25-256922_imab-ex99_1.htm:0]** 
- NovaBridge Biosciences also **appointed Mr. Ian Ying Woo as an independent member of its Board of Directors**, effective **October 15, 2025**.  **[1778016_0001193125-25-256922_everest_and_woo_pr_10-29.htm:0]** **[1778016_0001193125-25-256922_imab-ex99_1.htm:0]**  Mr. Woo is currently the President, Chief Financial Officer, and Director of Everest Medicines Limited.  **[1778016_0001193125-25-256922_everest_and_woo_pr_10-29.htm:0]** **[1778016_0001193125-25-256922_imab-ex99_1.htm:1]** 
- VIS-101 is a **novel bifunctional biologic** targeting VEGF-A and ANG-2, which is completing a Phase 2 study in China and is anticipated to be **Phase 3-ready in 2026**.  **[1778016_0001193125-25-256922_imab-ex99_1.htm:0]** **[1778016_0001193125-25-256922_imab-ex99_1.htm:1]**

NovaBridge Subsidiary Visara Assigns VIS-101 License to Everest Medicines; Appoints Ian Woo to Board

- **I-Mab** has officially changed its corporate name to **NovaBridge Biosciences**.  **[1778016_0001193125-25-256295_name_and_ticker_pr_10-29.htm:0]** 
- Effective **October 30, 2025**, the company's American Depositary Shares (ADSs) will commence trading on Nasdaq under the new ticker symbol **"NBP"**, replacing **"IMAB"**.  **[1778016_0001193125-25-256295_name_and_ticker_pr_10-29.htm:0]** **[1778016_0001193125-25-256295_imab-ex99_1.htm:0]** 
- The name change, approved by shareholders on **October 24, 2025**, reflects a strategic transformation to a global biotech platform, which includes plans for a **Hong Kong initial public offering (IPO)** and dual listings on Nasdaq and HKEX.  **[1778016_0001193125-25-256295_name_and_ticker_pr_10-29.htm:0]** **[1778016_0001193125-25-256295_imab-ex99_1.htm:0]** **[1778016_0001193125-25-256295_imab-ex99_1.htm:3]** 
- No action is required from current shareholders, and the CUSIP number for the ADSs remains unchanged.  **[1778016_0001193125-25-256295_name_and_ticker_pr_10-29.htm:0]** **[1778016_0001193125-25-256295_imab-ex99_1.htm:0]**

I-Mab Transitions to NovaBridge Biosciences with New Ticker NBP

- I-Mab's wholly owned subsidiary, I-Mab Biopharma Hong Kong Limited, **closed the acquisition** of Bridge Health Biotech Co., Ltd. on **October 28, 2025**.  **[1778016_0001193125-25-253456_bridge_health_close_-_10.htm:0]** 
- The transaction included an upfront payment of **$1.8 million** and non-contingent payments of **$1.2 million** through 2027.  **[1778016_0001193125-25-253456_bridge_health_close_-_10.htm:0]** 
- Bridge Health shareholders are eligible for future milestone payments of up to **$3.875 million**, contingent on the achievement of certain development and regulatory milestones.  **[1778016_0001193125-25-253456_bridge_health_close_-_10.htm:0]** 
- This acquisition provides I-Mab with rights to bispecific and multi-specific applications, including antibodies and antibody drug conjugates (ADCs), based on the Claudin 18.2 (CLDN18.2) parental antibody.  **[1778016_0001193125-25-253456_bridge_health_close_-_10.htm:0]**

I-Mab Completes Acquisition of Bridge Health Biotech

- I-Mab released updated Phase 1 monotherapy study results for **Givastomig**, a novel bispecific antibody, in **CLDN18.2-positive advanced Gastroesophageal Carcinoma (GEC)**.  **[1778016_0001193125-25-249612_3x_meeting_poster_-_24_o.htm:0]** **[1778016_0001193125-25-249612_imab-ex99_1.htm:0]** 
- The study, with data cut-off on **August 27, 2025**, showed Givastomig was **well tolerated**, with no dose-limiting toxicities observed up to 15mg/kg Q2W and 18 mg/kg Q3W, and the maximum-tolerated-dose was not reached.  **[1778016_0001193125-25-249612_imab-ex99_1.htm:1]** 
- In **45 heavily pre-treated GEC patients**, Givastomig demonstrated a **confirmed Overall Response Rate (ORR) of 18%** and a **Disease Control Rate (DCR) of 48.9%**.  **[1778016_0001193125-25-249612_imab-ex99_1.htm:2]**  
- The results indicate potential utility for Givastomig in patients with lower CLDN18.2 expression, as no statistically significant differences in efficacy were observed between CLDN18.2-high and CLDN18.2-low groups.  **[1778016_0001193125-25-249612_imab-ex99_1.htm:2]**  
- These findings support the continued development of Givastomig, including its evaluation as an add-on to first-line therapy.

I-Mab Reports Updated Phase 1 Monotherapy Results for Givastomig in Gastroesophageal Carcinoma

- I-Mab will present positive updated Phase 1 givastomig monotherapy data at the 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on **October 23, 2025**.  **[1778016_0001193125-25-246269_pr_-_triple_meeting_-_10.htm:0]** **[1778016_0001193125-25-246269_imab-ex99_1.htm:0]** 
- The updated data from 45 heavily pre-treated metastatic gastric cancer patients show an **18% Objective Response Rate (ORR)**, with responses observed across various dose ranges and CLDN18.2 expression levels, alongside **favorable overall safety**.  **[1778016_0001193125-25-246269_imab-ex99_1.htm:0]** **[1778016_0001193125-25-246269_imab-ex99_1.htm:1]** 
- These results support a combination clinical strategy for givastomig in first-line gastric cancer, a **$2 billion potential market**.  **[1778016_0001193125-25-246269_imab-ex99_1.htm:0]** 
- The company expects to report topline Phase 1b dose expansion combination data and initiate a global randomized Phase 2 study in **Q1 2026**.  **[1778016_0001193125-25-246269_imab-ex99_1.htm:0]** 
- I-Mab also announced its intention to change its name to **NovaBridge Bioscience**, pending Extraordinary General Meeting (EGM) approval on October 24, 2025.  **[1778016_0001193125-25-246269_imab-ex99_1.htm:2]**

I-Mab to Present Positive Givastomig Monotherapy Data and Announces Name Change

- I-Mab is undergoing a business transformation, evolving into **Nova Bridge**, a global biotech platform focused on bridging Asian innovation to global markets by leveraging discovery capabilities in China and clinical development in the U.S..  **[0001778016_2189455_0]** **[0001778016_2189455_1]** 
- The core strategy involves in-licensing clinical-stage assets, developing them to **proof of concept (POC)** within two to three years, and then potentially out-licensing, spinning off, or continuing late-phase development.  **[0001778016_2189455_3]** **[0001778016_2189455_13]** 
- As part of this strategy, I-Mab acquired **VIS 101**, a bifunctional biologic for wet AMD and DME, for **$37 million** for a controlling share of global rights, marking its entry into ophthalmology through a new subsidiary, Vice Sara.  **[0001778016_2189455_2]** **[0001778016_2189455_6]** 
- The phase two trial for VIS 101 is expected to read out top-line results by the **end of 2025 or Q1 2026**, with global phase three studies anticipated to begin in **2026**.  **[0001778016_2189455_8]**

I-Mab Unveils Nova Bridge Business Transformation and Key Acquisition

- I-Mab is undergoing a strategic transformation, rebranding to **NovoBridge**, and evolving into a **global biotech platform** with operations in China and the US.  **[0001778016_2189529_1]** 
- The new business model will focus on **in-licensing clinical-stage assets**, developing them to **proof-of-concept (POC)** within **2-3 years**, and then pursuing various exit strategies such as out-licensing or spin-offs.  **[0001778016_2189529_3]** 
- As part of this strategy, NovoBridge acquired global rights to **VS-101**, a bifunctional biologic for wet AMD and DME, for **$37 million** through a new subsidiary, Viscera.  **[0001778016_2189529_6]** 
- **Buwei**, founder and CEO of CBC Group, which manages over **$10 billion**, has been appointed **Executive Chairman of I-Mab (NovoBridge)**, bringing extensive investment and deal execution experience.  **[0001778016_2189529_1]** **[0001778016_2189529_11]** 
- The company confirmed its commitment to advancing existing clinical-stage assets, including **GivaStomig**, alongside the new platform strategy.  **[0001778016_2189529_4]** **[0001778016_2189529_11]**

I-Mab announces strategic transformation to NovoBridge and new platform business model

- I-Mab announced a **strategic transformation** to a global biotech platform and its intention to **rebrand as NovaBridge Biosciences**, pending shareholder approval at an Extraordinary General Meeting on **October 24, 2025**.  **[1778016_0001193125-25-241405_imab-ex99_1.htm:0]** **[1778016_0001193125-25-241405_business_update_10-16-25.htm:0]** **[1778016_0001193125-25-241405_imab-ex99_1.htm:5]** 
- The company intends to pursue a **Hong Kong initial public offering (IPO)** to achieve a dual listing on NASDAQ and the Hong Kong Stock Exchange (HKEX).  **[1778016_0001193125-25-241405_imab-ex99_1.htm:0]** **[1778016_0001193125-25-241405_business_update_10-16-25.htm:0]** **[1778016_0001193125-25-241405_business_update_10-16-25.htm:1]** 
- A newly formed subsidiary, **Visara, Inc.**, will acquire **VIS-101**, a novel bifunctional biologic, with I-Mab investing approximately **$37 million** in Visara's Series A preferred stock.  **[1778016_0001193125-25-241405_imab-ex99_1.htm:0]** **[1778016_0001193125-25-241405_business_update_10-16-25.htm:0]** 
- **Mr. Kyler Lei** has been appointed as the new **Chief Financial Officer**, effective **October 16, 2025**, replacing Mr. Joseph Skelton.  **[1778016_0001193125-25-241405_imab-ex99_1.htm:0]** **[1778016_0001193125-25-241405_business_update_10-16-25.htm:1]**

I-Mab Announces Strategic Transformation, Hong Kong IPO Intent, Rebranding, and CFO Appointment

- I-Mab reported a **net loss of $8.654 million** for the six months ended June 30, 2025, compared to a net income of $9.106 million for the same period in 2024, with research and development expenses decreasing by **63.9%** to **$4.1 million**.  **[1778016_0001193125-25-230890_imab-20250630.htm:7]** **[1778016_0001193125-25-230890_imab-20250630.htm:14]** 
- The company completed an underwritten offering on **August 5, 2025**, raising approximately **$61.2 million** in net proceeds from the issuance of **33,333,330 American depositary shares (ADSs)** at **$1.95 per ADS**.  **[1778016_0001193125-25-230890_imab-20250630.htm:3]** **[1778016_0001193125-25-230890_imab-20250630.htm:37]** 
- As of June 30, 2025, cash and cash equivalents increased significantly to **$165.404 million**, up from $68.263 million as of December 31, 2024.  **[1778016_0001193125-25-230890_imab-20250630.htm:13]** 
- I-Mab expects to acquire **Bridge Health Biotech Co., Ltd** early in the fourth quarter of 2025 for an upfront payment of **$1.8 million** and potential milestone payments, gaining rights to bispecific and multi-specific applications based on the Claudin 18.2 parental antibody.  **[1778016_0001193125-25-230890_imab-20250630.htm:37]** 
- The divestiture of its Greater China assets and business operations was completed on **April 2, 2024**, for an aggregate consideration of up to **$80 million** contingent on future milestones and royalties.  **[1778016_0001193125-25-230890_imab-20250630.htm:3]** **[1778016_0001193125-25-230890_imab-20250630.htm:17]**

NovaBridge Biosciences (IMAB)